Co-mutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1.
Understanding how two specific mutations work together in aggressive leukemia opens doors to better treatment strategies.
Co-mutations of asxl1 and IDH2 are associated with aggressive acute myeloid leukemia (AML), yet the underlying mechanisms have remained poorly understood. We generated a zebrafish model combining asxl1 mutation and IDH2R172K mutation that recapitulates the clinicopathologic and molecular features of high-risk AML with differentiation blockade and reduced animal survival.
What the study was
- Study design
- Observational/unspecified
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Blood advances
Why it surfaced
Score 6/10 [NOVEL_TREATMENT]: Observational/unspecified (Journal Article) matched 'Hematologic malignancies (AML, MDS, CLL,'. Components — novelty:2/3, relevance:2/3, design:1/2, population:1/2. Confidence: medium. Conservative scoring applied per v1.3 rubric.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.